Servier's Phase 3 INDIGO trial shows positive results for vorasidenib in IDH-mutant Glioma

Clinically meaningful achievement of primary and secondary endpoints is first major advance in treatment of low-grade glioma in more than 20 years Endpo...

 March 15, 2023 | News

Estrella Biopharma's ARTEMIS® T Cell Therapy EB103 IND Cleared by FDA for B-Cell Lymphomas Clinical Trial

Estrella Biopharma, Inc. ("Estrella"), a biopharmaceutical company whose mission is to harness the evolutionary power of the human immune system to transfo...

 March 09, 2023 | News

JW Therapeutics Starts Clinical Trial of Carteyva® for High-Risk Large B-Cell Lymphoma

High-risk large B-cell lymphoma includes large B-cell lymphoma with International Prognostic Index (IPI) score ≥3, and high-grade B-cell lymphoma (HGBL)...

 March 09, 2023 | News

Hummingbird Bioscience licenses Cancer Research UK's clinical trial results to support HMBD-001 development.

The Phase 1/2a clinical trial in the United Kingdom is being sponsored and managed by CRUK's Centre for Drug Development and led by Chief Investi...

 March 06, 2023 | News

Harbour BioMed's Batoclimab Shows Positive Results in Phase III Trial for Myasthenia Gravis

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel ant...

 March 06, 2023 | News

ExoCoBio Obtains GMP Licenses for Exosome Biopharmaceuticals and HA Dermal Fillers

ExoGMP™ is the world's largest exosome manufacturing facility in Osong, South Korea. Cellosome™ HA fillers are expected to be approved ...

 March 02, 2023 | News

Everest Medicines Commences Operations at State-of-the-Art mRNA Vaccine Facility.

 Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercializa...

 February 28, 2023 | News

Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase

In collaboration with researchers from the University of Shizuoka, Aji Bio-Pharma succeeded in developing a highly functional artificial RNA ligase using t...

 February 23, 2023 | News

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

Prior to this approval from the US FDA, Biosyngen's BRG01 was granted IND by China CDE on December 14th, 2022. In addition, China CDE has acknowledged...

 February 18, 2023 | News

Boan Biotech's Investigational Long-acting Anti-IL-4Rα Antibody BA2101 Administered for First Patient in Phase I Clinical Trial

BA2101 is the first long-acting anti-IL-4Rα monoclonal antibody that enters the clinical trial stage in the country. It is intended to be used for tr...

 February 16, 2023 | News

Boan Biotech's Investigational Anti-CD25 Antibody BA1106 Administered for First Patient in Phase I Clinical Trial

BA1106 is the first investigational anti-CD25 antibody to start clinical trials in China for treating solid tumors. Focusing on key therapeutic a...

 February 13, 2023 | News

Nectin Therapeutics to Collaborate with Merck on a Clinical Trial of Anti-PVR Antibody NTX1088

Nectin Therapeutics Ltd. (Nectin), a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune oncology tr...

 February 08, 2023 | News

Amjevita™ (Adalimumab-atto), First Biosimilar to Humira®, Now Available in the United States

Amgen (NASDAQ:AMGN)  announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the Un...

 February 01, 2023 | News

KBI Biopharma Announces Subcontract with Mapp Biopharmaceutical on Sudan ebolavirus Treatment

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. (Mapp) for the cont...

 January 23, 2023 | News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in